Abiopharma

News list

PDS BIOTECHNOLOGY CORP (PDSB)

SEC News
Aug. 11, 2026, 12:30 UTC

(85% Positive) PDS BIOTECHNOLOGY CORP (PDSB) Announces Enrollment Update for opportunities Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text

News bot Aug. 11, 2026, 12:35 p.m.

📋 PDS BIOTECHNOLOGY CORP (PDSB) - Clinical Trial Update

Filing Date: 2026-08-11

Accepted: 2026-08-11 08:30:33

Event Type: Clinical Trial Update

Event Details:

PDS BIOTECHNOLOGY CORP (PDSB) Announces Clinical Trial Update PDS BIOTECHNOLOGY CORP (PDSB) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: opportunities, challenges
Diseases/Conditions: cancer
Clinical Stage: Phase 2
Collaboration: PDS Biotechnology Corporation
- targeting and remodeling the tumor microenvironment, potentially enhancing the effectiveness and durability of current and emerging oncology therapies. To address this medical need, we have designed PDS0301
- targeting the tumor microenvironment rather than a single oncogenic pathway, PDS0301

🔬 Clinical Development Pipeline (PDS BIOTECHNOLOGY CORP):

Product	Type	Development Stage	Therapeutic Area	Source
Pembrolizumab Monotherapy	Drug	Phase PHASE3	Recurrent Head and Neck Cancer	ClinicalTrials.gov
Combination Treatment of PDS0101 and Pembrolizumab	Drug	Phase PHASE3	Recurrent Head and Neck Cancer	ClinicalTrials.gov
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7	Other	Phase PHASE1	High-risk HPV Infection and Biopsy-proven CIN1	ClinicalTrials.gov
Pembrolizumab (KEYTRUDA®) and PDS0101	Other	Phase PHASE2	Metastatic Head and Neck Cancer	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval: Not available
Executive Changes: Not available

Structured Data:

Company Name: PDS BIOTECHNOLOGY CORP
Ticker Symbol: PDSB